Oxford BioDynamics (LON:OBD) Trading Down 10.9% – Should You Sell?

Oxford BioDynamics Plc (LON:OBD) fell 10.9% during trading on Tuesday . The stock traded as low as GBX 0.45 ($0.01) and last traded at GBX 0.47 ($0.01). 585,995 shares were traded during mid-day trading, a decline of 98% from the average session volume of 26,710,965 shares. The stock had previously closed at GBX 0.53 ($0.01).

Analysts Set New Price Targets

Separately, Shore Capital reissued a “house stock” rating on shares of Oxford BioDynamics in a research note on Thursday, March 13th.

Oxford BioDynamics Stock Down 12.8 %

The firm has a market capitalization of £8.64 million, a price-to-earnings ratio of -0.08 and a beta of 0.42. The business has a 50 day simple moving average of GBX 0.59 and a 200-day simple moving average of GBX 1.65. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68.

Oxford BioDynamics (LON:OBD) last issued its earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.